Brainsway’s deep-TMS study in Obsessive Compulsive Disorder (OCD) Patients produces positive final results

Brainsway, located in Jerusalem, is preparing a submission to the FDA to market the device for Obsessive Compulsive Disorder (OCD) .

Its deep-TMS treatment led to statistically significant and meaningful improvements in patients suffering from OCD.

Patients who received active treatment were significantly better than those who received sham treatment.

For more information, see:

http://www.nasdaq.com/press-release/brainsway-announces-positive-final-results-of-its-deep-tms-multicenter-study-in-obsessive-20170612-00800